133 related articles for article (PubMed ID: 15486187)
1. Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.
Durbecq V; Paesmans M; Cardoso F; Desmedt C; Di Leo A; Chan S; Friedrichs K; Pinter T; Van Belle S; Murray E; Bodrogi I; Walpole E; Lesperance B; Korec S; Crown J; Simmonds P; Perren TJ; Leroy JY; Rouas G; Sotiriou C; Piccart M; Larsimont D
Mol Cancer Ther; 2004 Oct; 3(10):1207-14. PubMed ID: 15486187
[TBL] [Abstract][Full Text] [Related]
2. HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.
Di Leo A; Chan S; Paesmans M; Friedrichs K; Pinter T; Cocquyt V; Murray E; Bodrogi I; Walpole E; Lesperance B; Korec S; Crown J; Simmonds P; Von Minckwitz G; Leroy JY; Durbecq V; Isola J; Aapro M; Piccart MJ; Larsimont D
Breast Cancer Res Treat; 2004 Aug; 86(3):197-206. PubMed ID: 15567936
[TBL] [Abstract][Full Text] [Related]
3. p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial.
Di Leo A; Tanner M; Desmedt C; Paesmans M; Cardoso F; Durbecq V; Chan S; Perren T; Aapro M; Sotiriou C; Piccart MJ; Larsimont D; Isola J;
Ann Oncol; 2007 Jun; 18(6):997-1003. PubMed ID: 17369602
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
[TBL] [Abstract][Full Text] [Related]
5. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer.
Cardoso F; Durbecq V; Larsimont D; Paesmans M; Leroy JY; Rouas G; Sotiriou C; Renard N; Richard V; Piccart MJ; Di Leo A
Int J Oncol; 2004 Jan; 24(1):201-9. PubMed ID: 14654958
[TBL] [Abstract][Full Text] [Related]
6. Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.
Martin M; Romero A; Cheang MC; López García-Asenjo JA; García-Saenz JA; Oliva B; Román JM; He X; Casado A; de la Torre J; Furio V; Puente J; Caldés T; Vidart JA; Lopez-Tarruella S; Diaz-Rubio E; Perou CM
Breast Cancer Res Treat; 2011 Jul; 128(1):127-36. PubMed ID: 21465170
[TBL] [Abstract][Full Text] [Related]
7. HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.
Di Leo A; Larsimont D; Gancberg D; Jarvinen T; Beauduin M; Vindevoghel A; Michel J; Focan CH; Ries F; Gobert PH; Closon-Dejardin MT; Dolci S; Rouas G; Paesmans M; Lobelle JP; Isola J; Piccart MJ
Ann Oncol; 2001 Aug; 12(8):1081-9. PubMed ID: 11583189
[TBL] [Abstract][Full Text] [Related]
8. Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer.
Lynch BJ; Guinee DG; Holden JA
Hum Pathol; 1997 Oct; 28(10):1180-8. PubMed ID: 9343325
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response.
Rody A; Karn T; Gätje R; Ahr A; Solbach C; Kourtis K; Munnes M; Loibl S; Kissler S; Ruckhäberle E; Holtrich U; von Minckwitz G; Kaufmann M
Breast; 2007 Feb; 16(1):86-93. PubMed ID: 17010609
[TBL] [Abstract][Full Text] [Related]
10. The predictive and prognostic significance of pre- and post-treatment topoisomerase IIα in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer.
Chen S; Huang L; Liu Y; Chen CM; Wu J; Shao ZM
Eur J Surg Oncol; 2013 Jun; 39(6):619-26. PubMed ID: 23473851
[TBL] [Abstract][Full Text] [Related]
11. Correlation between topoisomerase-IIalpha gene amplification and protein expression in HER-2 amplified breast cancer.
Durbecq V; Desmed C; Paesmans M; Cardoso F; Di Leo A; Mano M; Rouas G; Leroy JY; Sotiriou C; Piccart M; Larsimont D
Int J Oncol; 2004 Nov; 25(5):1473-9. PubMed ID: 15492841
[TBL] [Abstract][Full Text] [Related]
12. Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel.
Galmarini CM; Treilleux I; Cardoso F; Bernard-Marty C; Durbecq V; Gancberg D; Bissery MC; Paesmans M; Larsimont D; Piccart MJ; Di Leo A; Dumontet C
Clin Cancer Res; 2008 Jul; 14(14):4511-6. PubMed ID: 18628466
[TBL] [Abstract][Full Text] [Related]
13. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS
Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926
[TBL] [Abstract][Full Text] [Related]
14. Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy.
Martin-Richard M; Muñoz M; Albanell J; Colomo L; Bellet M; Rey MJ; Tabernero J; Alonso C; Cardesa A; Gascon P; Fernandez PL
Oncology; 2004; 66(5):388-94. PubMed ID: 15331926
[TBL] [Abstract][Full Text] [Related]
15. Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial.
Erber R; Gluz O; Brünner N; Kreipe HH; Pelz E; Kates R; Bartels A; Huober J; Mohrmann S; Moustafa Z; Liedtke C; Möbus V; Augustin D; Thomssen C; Jänicke F; Kiechle M; Kuhn W; Nitz U; Harbeck N; Hartmann A
Breast Cancer Res Treat; 2015 Apr; 150(2):279-88. PubMed ID: 25721604
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
[TBL] [Abstract][Full Text] [Related]
17. [Relevance between TOP2A, EGFR gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer patients].
Liu L; Li XR; Hu YH; Zhang J
Zhonghua Yi Xue Za Zhi; 2016 Mar; 96(12):940-3. PubMed ID: 27045718
[TBL] [Abstract][Full Text] [Related]
18. Comparison of topoisomerase-IIalpha gene status between primary breast cancer and corresponding distant metastatic sites.
Durbecq V; Di Leo A; Cardoso F; Rouas G; Leroy JY; Piccart M; Larsimont D
Breast Cancer Res Treat; 2003 Feb; 77(3):199-204. PubMed ID: 12602919
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes.
Cardoso F; Di Leo A; Larsimont D; Gancberg D; Rouas G; Dolci S; Ferreira F; Paesmans M; Piccart M
Ann Oncol; 2001 May; 12(5):615-20. PubMed ID: 11432618
[TBL] [Abstract][Full Text] [Related]
20. Human epidermal growth factor receptor 2-positive breast cancer: heat shock protein 90 overexpression, Ki67 proliferative index, and topoisomerase II-α co-amplification as predictors of pathologic complete response to neoadjuvant chemotherapy with trastuzumab and docetaxel.
Bria E; Furlanetto J; Carbognin L; Brunelli M; Caliolo C; Nortilli R; Massari F; Pedron S; Manfrin E; Pellini F; Bonetti F; Sperduti I; Pollini GP; Scarpa A; Tortora G
Clin Breast Cancer; 2015 Feb; 15(1):16-23. PubMed ID: 25034441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
